{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:48:22Z","timestamp":1792788502570,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Semmelweis University","id":[{"id":"https:\/\/ror.org\/01g9ty582","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Econ Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The rising cost of new health technologies and limited healthcare budgets challenge health systems worldwide, including Oman. Local value judgments are crucial for informed decision-making. This study aims to establish a cost-effectiveness thresholds (CETs) framework for Oman, aligned with the country\u2019s economic status and healthcare priorities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The key findings from a recent literature review on global CETs and their applications were shared and discussed during a multi-stakeholder workshop in March 2024. Presenting these findings has provided participants a broad understanding of global CET practices and highlighted the use of multiple thresholds across different settings. Afterwards, a survey was distributed, asking participants to anonymously vote on six key concepts: the basis for the threshold, the baseline threshold multiplier, the use of multiple thresholds, the criteria for multiple thresholds, the number of multipliers, and which criterion should receive the 3X multiplier. The results from this voting guided the design and final agreement on the threshold values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty respondents supported adopting multiple CET values based on cost per quality-adjusted life-year (QALY), linked to Oman\u2019s economic status. A baseline CET equal to 1x Gross Domestic Product (GDP) per capita was suggested. Participants recommended three different threshold multipliers to reflect policy priorities. A continuous multiplier (1\u20133x GDP), based on incremental QALY gains, was used to favor technologies with greater health gains. Additionally, a fixed multiplier of 2 was chosen for both orphan drugs and treatments for priority diseases. The resulting CET values reflect technical and expert consensus and do not include patient or public perspectives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In Oman, the incremental cost per QALY gained should not exceed 1x GDP per capita for new health technologies that offer minimal health gains in common diseases. However, thresholds might increase to 12x GDP per capita for curative treatments in rare priority disease areas. It is recommended that CET values be reviewed and updated within three years, based on initial implementation experiences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13561-026-00817-w","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:54:23Z","timestamp":1784098463000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Establishing multiple cost-effectiveness thresholds in Oman: a stakeholder-driven approach"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7337-494X","authenticated-orcid":false,"given":"Said","family":"Wani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilal","family":"Alsabti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Allamki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Almandhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suleiman","family":"Alhajji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Alrashdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raid","family":"Alsabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Alqassabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Alzaabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Almaashani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia","family":"Alshuaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisa","family":"Rasool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asiya","family":"Alkindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra","family":"Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Alzadjali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Alrahbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khulood","family":"Almutawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Alansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mardheya","family":"Alkharusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadiya","family":"Albulushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Alghadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Aljaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safiya","family":"Almuaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Alkindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Alzawamri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Albalushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suha","family":"Allawati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhair","family":"Alsalti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Albalushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Nader","family":"Fasseeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Kalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"817_CR1","doi-asserted-by":"publisher","unstructured":"Lichtenberg FR. 23. The impact of biomedical innovation on longevity and health. Elgar Encyclopedia on the Economics of Knowledge and Innovation. 2022:186. https:\/\/doi.org\/10.5617\/njhe.1290.","DOI":"10.5617\/njhe.1290"},{"issue":"10","key":"817_CR2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.15171\/ijhpm.2019.36","volume":"8","author":"JP Grutters","year":"2019","unstructured":"Grutters JP, Govers T, Nijboer J, Tummers M, Van Der Wilt GJ, Rovers MM. Problems and promises of health technologies: the role of early health economic modeling. Int J health policy Manage. 2019;8(10):575. https:\/\/doi.org\/10.15171\/ijhpm.2019.36.","journal-title":"Int J health policy Manage"},{"key":"817_CR3","unstructured":"Chapman S, Paris V, Lopert R. Challenges in access to oncology medicines: Policies and practices across the OECD and the EU. 2020. https:\/\/www.oecd.org\/health\/health-systems\/Addressing-Challenges-in-Access-to-Oncology-Medicines-Analytical-Report.pdf. Accessed 04 April 2023."},{"issue":"1","key":"817_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00126450-200701000-00003","volume":"26","author":"AA Al Dhawi","year":"2007","unstructured":"Al Dhawi AA, West DJ Jr, Spinelli RJ, Gompf TA. The challenge of sustaining health care in Oman. Health Care Manag. 2007;26(1):19\u201330. https:\/\/doi.org\/10.1097\/00126450-200701000-00003.","journal-title":"Health Care Manag"},{"issue":"1","key":"817_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.18295\/2075-0528.1154","volume":"10","author":"MM Alshishtawy","year":"2010","unstructured":"Alshishtawy MM. Four decades of progress: Evolution of the health system in Oman. Sultan Qaboos Univ Med J. 2010;10(1):12. https:\/\/doi.org\/10.18295\/2075-0528.1154.","journal-title":"Sultan Qaboos Univ Med J"},{"key":"817_CR6","unstructured":"Food and Agriculture Organization of the United Nations. Oman Vision 2040. 2021. https:\/\/www.fao.org\/faolex\/results\/details\/en\/c\/LEX-FAOC201987\/#:~:text=The%20Sultanate%20aims%20to%20(i,to%2010%20percent%20of%20GDP. Accessed 12 May 2023."},{"key":"817_CR7","unstructured":"Oman Vision 2040. Oman Vision 2040, its priorities and objectives https:\/\/www.oman2040.om\/uploads\/publication\/20231105221146-2023-11-05publication221143_.pdf. Accessed 21 August 2024."},{"issue":"9","key":"817_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1108\/JHOM-01-2024-0012","volume":"38","author":"I Al Rashdi","year":"2024","unstructured":"Al Rashdi I, Al Balushi S, Al Shuaili A, Al Rashdi S, Ibrahim Al Bulushi N, Ibrahim Al Kindi A, et al. A roadmap towards implementing health technology assessment in Oman. J Health Organ Manag. 2024;38(9):241\u201357. https:\/\/doi.org\/10.1108\/JHOM-01-2024-0012.","journal-title":"J Health Organ Manag"},{"issue":"4","key":"817_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/1757975920909115","volume":"27","author":"H Al Hinai","year":"2020","unstructured":"Al Hinai H, Al Mufarji K, Al Siyabi H, Al Anqoudi Z, Al Saadi R, Al Awaidy S. Health promotion strategy as part of Vision 2050 in Oman: the way forward. Glob Health Promot. 2020;27(4):145\u20139. https:\/\/doi.org\/10.1177\/1757975920909115.","journal-title":"Glob Health Promot"},{"issue":"3","key":"817_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1017\/S0266462320000215","volume":"36","author":"B O\u2019Rourke","year":"2020","unstructured":"O\u2019Rourke B, Oortwijn W, Schuller T. The new definition of health technology assessment: A milestone in international collaboration. Int J Technol Assess Health Care. 2020;36(3):187\u201390. https:\/\/doi.org\/10.1017\/S0266462320000215.","journal-title":"Int J Technol Assess Health Care"},{"key":"817_CR11","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40273-017-0606-1","volume":"36","author":"P Thokala","year":"2018","unstructured":"Thokala P, Ochalek J, Leech AA, Tong T. Cost-effectiveness thresholds: the past, the present and the future. PharmacoEconomics. 2018;36:509\u201322. https:\/\/doi.org\/10.1007\/s40273-017-0606-1.","journal-title":"PharmacoEconomics"},{"issue":"1","key":"817_CR12","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/1471-2334-14-334","volume":"14","author":"ST Al Awaidy","year":"2014","unstructured":"Al Awaidy ST, Gebremeskel BG, Al Obeidani I, Al Baqlani S, Haddadin W, O\u2019Brien MA. Cost effectiveness of a pentavalent rotavirus vaccine in Oman. BMC Infect Dis. 2014;14(1):334. https:\/\/doi.org\/10.1186\/1471-2334-14-334.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"817_CR13","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1007\/s10198-021-01398-7","volume":"26","author":"A Hamad","year":"2023","unstructured":"Hamad A, Abdaljalil A, Abdellatif H, Aladarbeh Q, Al Farsi K, Alhuraiji A, et al. EE45 Cost-Effectiveness of Venetoclax in Combination with Rituximab in Relapsed\/Refractory Chroniclymphocytic Leukemia in Four Gulf Countries. Value Health. 2023;26(6):S67\u20138. https:\/\/doi.org\/10.1007\/s10198-021-01398-7.","journal-title":"Value Health"},{"issue":"6","key":"817_CR14","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/j.jval.2023.03.352","volume":"26","author":"D Soliman","year":"2023","unstructured":"Soliman D, Yasar N, Hawkshaw S. EE46 Cost-Effectiveness of Alpelisib Plus Fulvestrant in Postmenopausal Women with Hr+\/HER2-Advanced Breast Cancer (ABC) in Oman. Value Health. 2023;26(6):S68. https:\/\/doi.org\/10.1016\/j.jval.2023.03.352.","journal-title":"Value Health"},{"issue":"1","key":"817_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s42506-024-00159-7","volume":"99","author":"AN Fasseeh","year":"2024","unstructured":"Fasseeh AN, Korra N, Elezbawy B, Sedrak AS, Gamal M, Eldessouki R, et al. Framework for developing cost-effectiveness analysis threshold: the case of Egypt. J Egypt Public Health Assoc. 2024;99(1):12. https:\/\/doi.org\/10.1186\/s42506-024-00159-7.","journal-title":"J Egypt Public Health Assoc"},{"issue":"3","key":"817_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s40258-021-00710-z","volume":"20","author":"S Kov\u00e1cs","year":"2022","unstructured":"Kov\u00e1cs S, N\u00e9meth B, Erd\u0151si D, Brodszky V, Boncz I, Kal\u00f3 Z, et al. Should Hungary pay more for a QALY gain than higher-income Western European countries? Appl Health Econ Health Policy. 2022;20(3):291\u2013303. https:\/\/doi.org\/10.1007\/s40258-021-00710-z.","journal-title":"Appl Health Econ Health Policy"},{"issue":"11","key":"817_CR17","doi-asserted-by":"publisher","first-page":"e090344","DOI":"10.1136\/bmjopen-2024-090344","volume":"14","author":"S Aldallal","year":"2024","unstructured":"Aldallal S, Farghaly M, Fahmy S, Alnaqbi KA, Al Naeem W, Alsaadi M, et al. Thresholds for the value judgement of health technologies in the United Arab Emirates: a consensus approach through voting sessions. BMJ open. 2024;14(11):e090344. https:\/\/doi.org\/10.1136\/bmjopen-2024-090344.","journal-title":"BMJ open"},{"issue":"7","key":"817_CR18","doi-asserted-by":"publisher","first-page":"793","DOI":"10.18553\/jmcp.2019.18378","volume":"25","author":"LP Garrison","year":"2019","unstructured":"Garrison LP, Jackson T, Paul D, Kenston M. Value-based pricing for emerging gene therapies: the economic case for a higher cost-effectiveness threshold. J Manag Care Spec Pharm. 2019;25(7):793\u20139. https:\/\/doi.org\/10.18553\/jmcp.2019.18378.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"817_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jval.2019.10.005","volume":"23","author":"M Hasegawa","year":"2020","unstructured":"Hasegawa M, Komoto S, Shiroiwa T, Fukuda T. Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system. Value Health. 2020;23(1):43\u201351. https:\/\/doi.org\/10.1016\/j.jval.2019.10.005.","journal-title":"Value Health"},{"key":"817_CR20","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s40273-019-00810-8","volume":"37","author":"MM Versteegh","year":"2019","unstructured":"Versteegh MM, Ramos IC, Buyukkaramikli NC, Ansaripour A, Reckers-Droog VT, Brouwer WB. Severity-adjusted probability of being cost effective. PharmacoEconomics. 2019;37:1155\u201363. https:\/\/doi.org\/10.1007\/s40273-019-00810-8.","journal-title":"PharmacoEconomics"},{"key":"817_CR21","unstructured":"International Alliance of ALS\/MND Associations. US FDA Orphan Drug Designation. 2020. https:\/\/www.als-mnd.org\/support-for-pals-cals\/research\/us-fda-orphan-drug-designation\/. Accessed 1 May 2026."},{"key":"817_CR22","unstructured":"Oman Ministry of Health. Annual Health Report 2024 2024. https:\/\/www.moh.gov.om\/en\/statistics\/annual-health-reports\/annual-health-report-2024\/. Accessed 4 May 2026."},{"key":"817_CR23","unstructured":"Oman Ministry of Health. National NCD Survey 2025- Survey at a glance 2025. https:\/\/www.moh.gov.om\/en\/statistics\/studies-and-research\/national-ncd-survey-2025-survey-at-a-glance\/. Accessed 4 May 2026."},{"key":"817_CR24","unstructured":"Sultante of Oman Ministry of Health. Guidelines for Health Technology Assessment 2024. https:\/\/moh.gov.om\/media\/txzllfqa\/book.pdf. Accessed 2 May 2026."},{"issue":"7","key":"817_CR25","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jval.2017.12.016","volume":"21","author":"AA Leech","year":"2018","unstructured":"Leech AA, Kim DD, Cohen JT, Neumann PJ. Use and misuse of cost-effectiveness analysis thresholds in low-and middle-income countries: trends in cost-per-DALY studies. Value Health. 2018;21(7):759\u201361. https:\/\/doi.org\/10.1016\/j.jval.2017.12.016.","journal-title":"Value Health"},{"issue":"1","key":"817_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/13696998.2022.2157141","volume":"26","author":"AH Al-Jedai","year":"2023","unstructured":"Al-Jedai AH, Lomas J, Almudaiheem HY, Al-Ruthia YSH, Alghamdi S, Awad N, et al. Informing a cost-effectiveness threshold for Saudi Arabia. J Med Econ. 2023;26(1):128\u201338. https:\/\/doi.org\/10.1080\/13696998.2022.2157141.","journal-title":"J Med Econ"},{"key":"817_CR27","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s40273-014-0204-4","volume":"32","author":"M Paulden","year":"2014","unstructured":"Paulden M, O\u2019Mahony JF, Culyer AJ, McCabe C. Some inconsistencies in NICE\u2019s consideration of social values. PharmacoEconomics. 2014;32:1043\u201353. https:\/\/doi.org\/10.1007\/s40273-014-0204-4.","journal-title":"PharmacoEconomics"},{"issue":"5","key":"817_CR28","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2217\/cer.15.38","volume":"4","author":"R Schwarzer","year":"2015","unstructured":"Schwarzer R, Rochau U, Saverno K, Jahn B, Bornschein B, Muehlberger N, et al. Systematic overview of cost\u2013effectiveness thresholds in ten countries across four continents. J Comp Eff Res. 2015;4(5):485\u2013504. https:\/\/doi.org\/10.2217\/cer.15.38.","journal-title":"J Comp Eff Res"},{"issue":"1","key":"817_CR29","doi-asserted-by":"publisher","first-page":"27902","DOI":"10.3402\/jmahp.v3.27902","volume":"3","author":"M Toumi","year":"2015","unstructured":"Toumi M, R\u00e9muzat C, El Hammi E, Millier A, Aball\u00e9a S, Chouaid C, et al. Current process and future path for health economic assessment of pharmaceuticals in France. J market access health policy. 2015;3(1):27902. https:\/\/doi.org\/10.3402\/jmahp.v3.27902.","journal-title":"J market access health policy"},{"key":"817_CR30","doi-asserted-by":"publisher","first-page":"175883592091600","DOI":"10.1177\/1758835920916000","volume":"12","author":"B Wu","year":"2020","unstructured":"Wu B, Ma F. Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer. Therapeutic Adv Med Oncol. 2020;12:1758835920916000. https:\/\/doi.org\/10.1177\/1758835920916000.","journal-title":"Therapeutic Adv Med Oncol"}],"container-title":["Health Economics Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13561-026-00817-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-026-00817-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-026-00817-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:09:04Z","timestamp":1791763744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13561-026-00817-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["817"],"URL":"https:\/\/doi.org\/10.1186\/s13561-026-00817-w","relation":{},"ISSN":["2191-1991"],"issn-type":[{"value":"2191-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Syreon Middle East acknowledges Novartis for its financial support in conducting the study. Ahmad Nader Fasseeh and Zolt\u00e1n Kal\u00f3 are shareholders in Syreon Middle East. The remaining authors declare that the research was conducted without any commercial or financial relationships that could be seen as a potential conflict of interest. The funder was not involved in the study design, data collection, data analysis, data interpretation, or manuscript writing.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"113"}}